Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11044975 | 0.68 | USP2 (0.41) | ADORA2BALDH1A1USP2KDM4EMAPT | |
| SCHEMBL13247692 | 0.67 | USP2 (0.43) | ADORA2BALDH1A1USP2MAPTLMNA | |
| SCHEMBL20432259 | 0.66 | USP2 (0.45) | ADORA2BALDH1A1USP2LMNAHTT | |
| SCHEMBL24669059 | 0.66 | CYP3A4 (0.76) | ADORA2BALDH1A1USP2KDM4EMAPT | |
| SCHEMBL9167977 | 0.65 | ALDH1A1 (0.65) | ADORA2BALDH1A1USP2KDM4EMAPT | |
| SCHEMBL11044972 | 0.65 | ADORA2B (0.42) | ADORA2BALDH1A1USP2KDM4EMAPT | |
| SCHEMBL2704481 | 0.65 | KMT2A (0.59) | ADORA2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL19246063 | 0.64 | MEN1 (0.48) | ADORA2BALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL5688389 | 0.64 | ADORA2B (0.51) | ADORA2B | |
| SCHEMBL5718940 | 0.64 | USP2 (0.72) | ADORA2BALDH1A1USP2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2012-08-09 | — | — | US | disclosed |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | disclosed |
| EP-1982704-A2 | New molecular target of neurotoxicity | Exonhit Therapeutics SA (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | disclosed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1417349-A2 | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY | Exonhit Therapeutics S.A. (FR) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003016563-A2 | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2003-02-27 | — | — | WO | disclosed |
| EP-0049494-B1 | ESTERS OF 7-HYDROXYALKYL-1,3-DIMETHYL XANTHINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS LIPID DIMINISHERS | King Consult GmbH (DE) | 1985-04-17 | — | — | EP | disclosed |
| EP-0049494-A1 | Esters of 7-hydroxyalkyl-1,3-dimethyl xanthines, process for their preparation and their application as lipid diminishers | King Consult GmbH (DE) | 1982-04-14 | — | — | EP | disclosed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | PDE4B, PDE4A, PDE4D | ADORA2B 481/4885ALDH1A1 1640/4885USP2 780/4885 |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | ADORA2B 818/4885ALDH1A1 1463/4885USP2 1101/4885 |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | ADORA2B 818/4885ALDH1A1 1463/4885USP2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.